Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results from a new drug study caused investors to flee the drugmaker.
The Danish producer of Ozempic, Wegovy, and Semaglutide said clinical trials had demonstrated that overweight subjects using the weight-loss drug Cagrisema had lost an average of 22.7% of their weight over the 68-week trial, compared to 2.3% for those using a placebo.
